Stock Research: Hanall Biopharma

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Hanall Biopharma

KOSE:A009420 KR7009420001
37
  • Value
    34
  • Growth
    98
  • Safety
    Safety
    1
  • Combined
    35
  • Sentiment
    60
  • 360° View
    360° View
    37
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Hanall Biopharma Co Ltd is a Korea-based company that manufactures and distributes synthetic pharmaceuticals and biopharmaceuticals. The company operates in the pharmaceutical industry, producing drugs for various conditions including diabetes, skin issues, and cardiovascular diseases. It distributes its products in domestic and overseas markets. In the last fiscal year, the company had a market cap of $993 million, profits of $50 million, and revenue of $94 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 37 (better than 37% compared with alternatives), overall professional sentiment and financial characteristics for the stock Hanall Biopharma are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Hanall Biopharma. The consolidated Growth Rank has a good rank of 98, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 98% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 60, which means that professional investors are more optimistic about the stock than for 60% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 1, which means that the share price of Hanall Biopharma is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 99% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 34, which means that the company has a financing structure that is riskier than those of 66% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
KOSPI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
1 4 4 7
Growth
98 100 99 1
Safety
Safety
34 59 72 74
Sentiment
60 54 78 63
360° View
360° View
37 56 79 13
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
75 76 76 100
Opinions Change
50 50 50 50
Pro Holdings
n/a 36 64 1
Market Pulse
55 48 63 60
Sentiment
60 54 78 63
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
1 4 4 7
Growth
98 100 99 1
Safety Safety
34 59 72 74
Combined
35 55 60 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
1 1 3 9
Price vs. Earnings (P/E)
8 7 5 9
Price vs. Book (P/B)
5 8 5 9
Dividend Yield
1 1 1 1
Value
1 4 4 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
93 87 44 38
Profit Growth
96 98 100 18
Capital Growth
89 84 89 12
Stock Returns
30 72 100 7
Growth
98 100 99 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
87 93 93 92
Refinancing
8 12 19 23
Liquidity
20 63 70 84
Safety Safety
34 59 72 74

Similar Stocks

Discover high‑ranked alternatives to Hanall Biopharma and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Korea Investment

KOSE:A071050
Country: South Korea
Industry: Investment Banking & Brokerage
Size: Large
Full Stock Analysis

Kia Motors

KOSE:A000270
Country: South Korea
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Tsumura

TSE:4540
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.